Stephen F. Betz - Mar 31, 2022 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Scientific Officer
Signature
/s/ Marc Wilson, as attorney-in-fact
Stock symbol
CRNX
Transactions as of
Mar 31, 2022
Transactions value $
-$178,475
Form type
4
Date filed
4/1/2022, 05:39 PM
Previous filing
Mar 17, 2022
Next filing
Apr 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Sale -$87.7K -4.16K -3.11% $21.06 130K Mar 31, 2022 Direct F1, F2
transaction CRNX Common Stock Sale -$90.8K -4.16K -3.21% $21.80 126K Apr 1, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.
F2 The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $21.0614 per share. The range of sales prices on the transaction date was $21.0201 to $21.0774 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.